Neusoft Medical Systems Showcases AI-powered Medical Imaging Solutions at RSNA 2024

December 03, 2024 12:50 PM AEDT | By Cision

Neusoft Medical Systems Showcases AI-powered Medical Imaging Solutions at RSNA 2024 — Image source: Kalkine Media

Recent News

247connect Makes Remote Desktop Access Simple and Affordable!

Monroe Capital, SMBC and MA Financial Launch US$1.7 Billion Middle Mar...

Kasada’s Q1 2025 Threat Intel Report Uncovers ALTSRUS “Reverse Robin H...

Asana Launches Smart Workflow Gallery, a Blueprint for Effective Human...

CHICAGO, Dec. 3, 2024 /PRNewswire/ -- Neusoft Medical Systems Co., Ltd. ("Neusoft Medical Systems"), a global leader in medical imaging solutions and services, is proud to announce its participation in the Radiological Society of North America (RSNA) 2024 Annual Meeting, taking place in Chicago from December 1-5.

RSNA is the world's premier scientific and educational event for the radiological sciences, bringing together leading professionals from around the globe. At this year's meeting, Neusoft Medical Systems is showcasing its cutting-edge portfolio of AI-powered medical imaging technologies designed to enhance diagnostic precision, streamline clinical workflows, and expand access to quality care globally.

"At Neusoft Medical Systems, we empower radiologists to address clinical challenges while enhancing the accessibility and affordability of medical imaging for regions and communities in need," said Patrick Wu, CEO of Neusoft Medical Systems. "By integrating advanced medical imaging, artificial intelligence, and clinical expertise, we aim to provide caregivers with comprehensive tools for accurate diagnoses. We look forward to engaging with industry leaders at RSNA 2024 to further advance healthcare through innovation."

The booth features a variety of groundbreaking innovations, including:

NeuViz Epoch+ CT: A 512-slice CT capable of freezing cardiac in one beat by 0.235s ultra-fast rotation speed. Its AI-powered ClearInfinity reconstruction delivers ultra-low-dose imaging with superior resolution.
NeuMR Universal: The industry's first Dual-energy 3.0T MRI, featuring the revolutionary Dual-energy Gradient System. This innovative design provides explosive power in gradient output and remarkable staying power, ensuring a stable gradient waveform.
NeuAngio-CT Plus: A high-end, wide-coverage Angio-CT system offering a comprehensive one-stop solution for interventional diagnosis and treatment. It streamlines surgical workflows by integrating preoperative planning, intraoperative guidance, and postoperative evaluation into a single platform, significantly improving operational efficiency.
NeuEra PET/CT: The world's first 180ps grade fully digitized PET/CT, achieving a qualitative leap from 3 minutes for a single bed in the clinical detection process to an extremely fast scan of 15 seconds.

For further information, please visit www.neusoftmedical.com/en

About Neusoft Medical Systems

Neusoft Medical Systems Co., Ltd. is a global leader in medical imaging solutions and services, delivering intelligent, efficient, precise, and secure products to customers worldwide. Serving over 13,000 medical institutions in 110+ countries, the company has installed more than 47,000 units globally, covering diverse categories, grades, and customer segments.

* Not all equipment models and services featured in this press are available in every region of the world.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.